Literature DB >> 23036264

Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea.

Roland von Känel1, Loki Natarajan, Sonia Ancoli-Israel, Paul J Mills, Tanya Wolfson, Anthony C Gamst, José S Loredo, Joel E Dimsdale.   

Abstract

OBJECTIVE: Obstructive sleep apnea (OSA) has been associated with an increased risk of atherothrombotic events. A prothrombotic state might partially explain this link. This study investigated OSA patients' day/night rhythm of several prothrombotic markers and their potential changes with therapeutic continuous positive airway pressure (CPAP).
METHODS: The study included 51 OSA patients [apnea hypopnea index (AHI) ⩾10] and 24 non-OSA controls (AHI<10). Of the 51 OSA patients, 25 were randomized to CPAP and 26 to placebo-CPAP. Twelve blood samples were collected over a 24h period to measure prothrombotic markers. For the apneic patients these samples were collected before treatment and after 3weeks of treatment with either CPAP or placebo-CPAP. Day/night variation in prothrombotic markers was examined using a cosinor analysis.
RESULTS: Compared with controls, OSA patients showed lower mesor (mean) and amplitude (difference between maximum and minimum activity) of D-dimer. In unadjusted (but not in adjusted) analysis, patients showed higher mesor of plasminogen activator inhibitor-1 (p<0.05 in all cases). No significant group differences were seen in mesor and amplitude for either soluble tissue factor or von Willebrand factor, or the acrophase (time of the peak) and periodic pattern for any prothrombotic markers. There were no significant differences in changes of periodic pattern and in day/night rhythm parameters of prothrombotic markers pre- to post-treatment between the CPAP and placebo condition.
CONCLUSIONS: There may be altered day/night rhythm of some prothrombotic markers in OSA patients compared with controls. CPAP treatment for 3weeks did not affect day/night rhythm of prothrombotic markers in OSA patients differently from placebo-CPAP.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036264      PMCID: PMC3540139          DOI: 10.1016/j.sleep.2012.07.009

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  49 in total

1.  Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up.

Authors:  Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

2.  What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models.

Authors:  Michael A Babyak
Journal:  Psychosom Med       Date:  2004 May-Jun       Impact factor: 4.312

3.  Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study.

Authors:  Susan Redline; Gayane Yenokyan; Daniel J Gottlieb; Eyal Shahar; George T O'Connor; Helaine E Resnick; Marie Diener-West; Mark H Sanders; Philip A Wolf; Estella M Geraghty; Tauqeer Ali; Michael Lebowitz; Naresh M Punjabi
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

4.  Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients.

Authors:  C Rångemark; J A Hedner; J T Carlson; G Gleerup; K Winther
Journal:  Sleep       Date:  1995-04       Impact factor: 5.849

5.  Sleep and biomarkers of atherosclerosis in elderly Alzheimer caregivers and controls.

Authors:  Roland von Känel; Sonia Ancoli-Israel; Joel E Dimsdale; Paul J Mills; Brent T Mausbach; Michael G Ziegler; Thomas L Patterson; Igor Grant
Journal:  Gerontology       Date:  2009-12-03       Impact factor: 5.140

6.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

7.  Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome.

Authors:  Joji Ishikawa; Satoshi Hoshide; Kazuo Eguchi; Shizukiyo Ishikawa; Thomas G Pickering; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Hypertens       Date:  2008-06       Impact factor: 4.844

8.  Hemostatic implications of endothelial cell apoptosis in obstructive sleep apnea.

Authors:  Ali A El Solh; Morohunfolu E Akinnusi; Ilya G Berim; A Misha Peter; Linda L Paasch; Kristie R Szarpa
Journal:  Sleep Breath       Date:  2008-04-09       Impact factor: 2.816

9.  Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population.

Authors:  Alicja R Rudnicka; Ann Rumley; Gordon D O Lowe; David P Strachan
Journal:  Circulation       Date:  2007-02-12       Impact factor: 29.690

10.  von Willebrand Factor in CHD and stroke: relationships and therapeutic implications.

Authors:  Marie-Therese Cooney; Alexandra L Dudina; Patrick O'Callaghan; Ian M Graham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06
View more
  9 in total

Review 1.  The role inflammatory response genes in obstructive sleep apnea syndrome: a review.

Authors:  Francisco Fábio Ferreira de Lima; Diego R Mazzotti; Sergio Tufik; Lia Bittencourt
Journal:  Sleep Breath       Date:  2015-07-23       Impact factor: 2.816

Review 2.  Cardiovascular outcomes of continuous positive airway pressure therapy for obstructive sleep apnea.

Authors:  Yüksel Peker; Baran Balcan
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

3.  Serum levels of trace minerals and heavy metals in severe obstructive sleep apnea patients: correlates and clinical implications.

Authors:  Selvi Asker; Muntecep Asker; Asli Cilingir Yeltekin; Mehmet Aslan; Halit Demir
Journal:  Sleep Breath       Date:  2014-08-09       Impact factor: 2.816

Review 4.  Obstructive sleep apnea syndrome: coagulation anomalies and treatment with continuous positive airway pressure.

Authors:  Domenico Maurizio Toraldo; Michele De Benedetto; Egeria Scoditti; Francesco De Nuccio
Journal:  Sleep Breath       Date:  2015-07-14       Impact factor: 2.816

5.  Obstructive sleep apnea might trigger acute pulmonary embolism: results from a cohort study.

Authors:  T M Berghaus; A Witkowska; T Wagner; C Faul; M Schwaiblmair; W von Scheidt
Journal:  Clin Res Cardiol       Date:  2016-06-16       Impact factor: 5.460

6.  Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study.

Authors:  L Kheirandish-Gozal; A Gileles-Hillel; M L Alonso-Álvarez; E Peris; R Bhattacharjee; J Terán-Santos; J Duran-Cantolla; D Gozal
Journal:  Int J Obes (Lond)       Date:  2015-03-24       Impact factor: 5.095

Review 7.  Coagulation and Fibrinolysis in Obstructive Sleep Apnoea.

Authors:  Andras Bikov; Martina Meszaros; Esther Irene Schwarz
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

8.  Pathophysiologic mechanisms of cardiovascular disease in obstructive sleep apnea syndrome.

Authors:  Carlos Zamarrón; Luis Valdés Cuadrado; Rodolfo Alvarez-Sala
Journal:  Pulm Med       Date:  2013-06-27

9.  Endothelial dysfunction in obstructive sleep apnea patients.

Authors:  Michał Harańczyk; Małgorzata Konieczyńska; Wojciech Płazak
Journal:  Sleep Breath       Date:  2021-05-07       Impact factor: 2.816

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.